BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 109501)

  • 1. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
    Jones RJ
    J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled trials of a polyvalent pseudomonas vaccine in burns.
    Jones RJ; Roe EA; Gupta JL
    Lancet; 1979 Nov; 2(8150):977-82. PubMed ID: 91774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of a polyvalent vaccine against Pseudomonas aeruginosa in severely burned patients].
    Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
    Pol Tyg Lek; 1984 Apr; 39(17):557-61. PubMed ID: 6435103
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use of polyvalent vaccine against Pseudomonas aeruginosa in extensive burns].
    Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
    Pol Tyg Lek; 1981 Aug; 36(32):1207-11. PubMed ID: 6798556
    [No Abstract]   [Full Text] [Related]  

  • 7. Low mortality in burned patients in a Pseudomonas vaccine trial.
    Jones RJ; Roe EA; Gupta JL
    Lancet; 1978 Aug; 2(8086):401-3. PubMed ID: 79764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-linked immunosorbent assay (ELISA) and a passive haemagglutination test (PHT) for the detection of pseudomonas antibodies in burned patients.
    Roe EA; Jones RJ
    Burns Incl Therm Inj; 1985 Apr; 11(4):252-8. PubMed ID: 3924353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
    Ionescu A; Meitert E; Vasiliu S; Meitert T; Milicescu S; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594
    [No Abstract]   [Full Text] [Related]  

  • 11. Active and passive immunization against Pseudomonas aeruginosa infection of burned patients.
    Roe EA; Jones RJ
    Burns Incl Therm Inj; 1983 Jul; 9(6):433-9. PubMed ID: 6412970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa: prevention better than cure?
    Mellor JA; Miler JJ
    Dev Biol Stand; 1979; 43():53-9. PubMed ID: 118071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.
    Jones RJ; Roe EA; Gupta JL
    Lancet; 1980 Dec; 2(8207):1263-5. PubMed ID: 6108445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.
    Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB
    FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 17. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].
    Schiller B; Buchowicz I; Lysakowska E; Sakiel S; Korbecki M
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):30-2. PubMed ID: 2409720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological failure of Pseudomonas vaccination in patients receiving multiple chemotherapy.
    Bannister P; Mellor J
    J Biol Stand; 1985 Oct; 13(4):321-6. PubMed ID: 3932361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa ribosomal vaccine. A comparison of the immunogenicity of vaccines from two different serotypes.
    Lieberman MM
    Antibiot Chemother (1971); 1989; 42():193-202. PubMed ID: 2512837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.